Streetbeat News

Stock Prices

JAKK

Analysts have shown a bullish sentiment towards Jakks Pacific (NASDAQ:JAKK) with a 29.17% increase in the average 12-month price target. The company has strong financial metrics, including a high net margin and effective debt management.

Portfolio Pulse from Benzinga Insights

September 17, 2024 | 12:02 pm

ANIP

ANI Pharmaceuticals (NASDAQ:ANIP) has been analyzed by four analysts, showing a range of perspectives from bullish to bearish. The average 12-month price target is $85.5, with a high of $94.00 and a low of $60.00. Analysts have decreased the average price target by 3.66%. The company has shown a revenue growth rate of 18.44% and maintains a strong financial position with a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 17, 2024 | 12:02 pm

LSCC

Lattice Semiconductor (NASDAQ:LSCC) has received mixed analyst ratings over the past three months, with a decrease in the average 12-month price target from $77.55 to $62.08. Analysts have adjusted their ratings and price targets, reflecting varied sentiments about the company's financial health and market position.

Portfolio Pulse from Benzinga Insights

September 17, 2024 | 12:01 pm

DOCS

Doximity (NYSE:DOCS) has been analyzed by 10 analysts, showing a range of sentiments from bullish to bearish. Recent analyst actions include several rating upgrades and increased price targets, with an average 12-month price target of $33.4. Doximity's financial performance is strong, with notable revenue growth, high net margins, and effective debt management.

Portfolio Pulse from Benzinga Insights

September 17, 2024 | 12:01 pm

GGR

GOTU

TAL

The article highlights three oversold consumer discretionary stocks with potential for short-term gains: TAL Education Group, Gaotu Techedu Inc, and Gogoro Inc. These stocks have RSI values indicating they are oversold, suggesting potential buying opportunities.

Portfolio Pulse from Avi Kapoor

September 17, 2024 | 12:00 pm

DV

DoubleVerify Holdings (NYSE:DV) has been analyzed by 9 analysts, showing a range of ratings from bullish to indifferent. The average 12-month price target is $27.78, down 6.72% from the previous $29.78. Analysts have maintained or adjusted their ratings and price targets, reflecting their views on the company's market position and financial performance.

Portfolio Pulse from Benzinga Insights

September 17, 2024 | 12:00 pm

IMCR

Immunocore Holdings (NASDAQ:IMCR) has been analyzed by 7 analysts, showing a range of opinions from bullish to bearish. The average 12-month price target is $82.86, with a high of $100 and a low of $66. Recent evaluations show a decline in the average price target from $87.29. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. Immunocore is a biotechnology company focused on TCR bispecific immunotherapies, with significant revenue from the US. Despite a positive revenue growth rate of 26.18%, the company faces challenges with a high debt-to-equity ratio and negative net margin.

Portfolio Pulse from Benzinga Insights

September 17, 2024 | 12:00 pm

HOTH

Hoth Therapeutics announced that a recent study using Alzheimer's model mice treated with HT-ALZ showed reductions in astrocyte activity in certain brain areas.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:59 am

MRK

SMMT

Merck & Co Inc (MRK) and Daiichi Sankyo's lung cancer drug, patritumab deruxtecan, met its primary endpoint in a phase 3 trial, showing significant improvement in progression-free survival for EGFR-mutated NSCLC patients. The safety profile was consistent with previous trials. Meanwhile, Summit Therapeutics' ivonescimab showed better results than Merck's Keytruda in a separate trial.

Portfolio Pulse from Vandana Singh

September 17, 2024 | 11:58 am

DRMA

Dermata Therapeutics shares fell following the announcement of a $3.5 million private placement involving 1,912,569 shares of common stock and short-term series B warrants priced at $1.83 per share.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 11:56 am